Login / Signup

Letter: new thresholds need to be defined when using point of care assays to monitor infliximab trough levels in IBD patients.

D DutzerY NasserA E BergerXavier RoblinStephane Paul
Published in: Alimentary pharmacology & therapeutics (2019)
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • ulcerative colitis
  • single cell